Royal Bank Of Canada Has Lowered Expectations for Alkermes (NASDAQ:ALKS) Stock Price

Alkermes (NASDAQ:ALKS) had its target price decreased by stock analysts at Royal Bank Of Canada from $47.00 to $45.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 49.50% from the stock’s previous close.

A number of other research firms have also recently weighed in on ALKS. Wolfe Research initiated coverage on shares of Alkermes in a research report on Monday. They set an “outperform” rating and a $45.00 price objective for the company. Bank of America lifted their target price on Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, February 20th. Needham & Company LLC upped their target price on shares of Alkermes from $43.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.07.

Alkermes Stock Performance

ALKS opened at $30.10 on Thursday. The stock has a market capitalization of $5.02 billion, a PE ratio of 21.05 and a beta of 0.49. Alkermes has a one year low of $25.17 and a one year high of $36.32. The business’s 50 day moving average price is $31.54 and its 200 day moving average price is $30.20.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The business had revenue of $384.55 million during the quarter, compared to analysts’ expectations of $380.44 million. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. Alkermes’s revenue for the quarter was down 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.05 EPS. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, equities research analysts forecast that Alkermes will post 1.31 earnings per share for the current fiscal year.

Insider Transactions at Alkermes

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the transaction, the executive vice president directly owned 57,740 shares of the company’s stock, valued at $1,959,118.20. This represents a 13.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Shane Cooke sold 61,200 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the sale, the director directly owned 103,744 shares in the company, valued at approximately $3,586,430.08. The trade was a 37.10% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 148,148 shares of company stock worth $5,028,378. Company insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in Alkermes by 117.2% in the first quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock valued at $9,098,000 after acquiring an additional 148,696 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in Alkermes during the 1st quarter worth approximately $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Alkermes by 4.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock worth $15,927,000 after buying an additional 20,091 shares during the period. State of New Jersey Common Pension Fund D boosted its holdings in shares of Alkermes by 15.1% in the second quarter. State of New Jersey Common Pension Fund D now owns 62,677 shares of the company’s stock valued at $1,793,000 after acquiring an additional 8,214 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Alkermes by 1.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock valued at $1,249,000 after acquiring an additional 551 shares during the period. 95.21% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analyst optimism — Wells Fargo raised its price target to $43 and kept an overweight stance, signaling bullish analyst conviction that shares have meaningful upside. Wells Fargo raises price target to $43
• Positive Sentiment: RBC still rates ALKS “outperform” and keeps a high price target ($45 after a small cut), indicating continued buy-side support from some sell-side analysts. RBC maintains outperform, lowers PT to $45
• Neutral Sentiment: CEO succession announced — Alkermes disclosed a leadership transition plan; such changes create short-term uncertainty but may be neutral-to-positive over time depending on execution. Alkermes announces CEO succession plan
• Neutral Sentiment: Revenue roughly in line/beat estimates while EPS missed — top-line results were not the primary problem; profitability and EPS dynamics drove the negative reaction. See earnings highlights and call transcript for detail. Q4 2025 earnings highlights
• Negative Sentiment: Earnings miss and downbeat near-term outlook — reported EPS (~$0.29) missed the ~$0.43 consensus and management set FY2026 EPS guidance in negative territory, undercutting the bull case and spurring the sell-off. Shares down after earnings miss
• Negative Sentiment: Market reaction — shares declined sharply on the news and trading volume picked up, reflecting short-term repositioning by investors. Coverage pieces and call transcripts detail investor pushback. ALKS down despite mixed results, leadership change
• Neutral Sentiment: Short-interest reporting in feeds shows inconclusive/zeroed data for February (no actionable signal from that dataset). Short interest note

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.